A Double-Blind, Placebo Controlled Trial of Intravenous Immunoglobulin Therapy in Patient With Small Fiber Neuropathy Associated With Autoantibodies to TS-HDS and FGFR3
Latest Information Update: 15 Sep 2023
Price :
$35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- 08 Dec 2022 Status changed from active, no longer recruiting to completed.
- 16 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.